Intuitive Surgical, Inc. (ISRG) Stock: Price, Forecast & Analyst Target
Intuitive Surgical, Inc. (ISRG) — MoonshotScore 94/100 (Exceptional band), calculated Nov 18, 2026. Price $420.95 (-2.23%), as of the Nov 18, 2026 trading session; market cap $146B. Expected results Jan 28, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Intuitive Surgical, Inc. · ISRG · NASDAQ · Healthcare · Medical - Instruments & Supplies
Research dated 2026-11-06: Intuitive Surgical sells the da Vinci surgical robot and the Ion lung-biopsy platform to hospitals, then keeps earning from each installed system through the instruments, accessories and service contracts that procedures consume. Its latest quarter produced the highest revenue and operating cash flow in the displayed history at the same time as a steep fall in reported operating profit, so separating a sudden jump in administrative expense from the steady growth of the installed base is what matters most for reading the stock now.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Intuitive Surgical (ISRG)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality, a fortress balance sheet and elite growth, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Fortress; Valuation: Rich; Growth Durability: Compounding; Momentum: Rising.
- EPS beat 0 of the last 4 reports
- expected results Jan 28, 2027
- Altman Z 29.72 · Piotroski F 7
Helping: business quality, balance-sheet strength, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 94 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional | |
| 94 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $420.95 | |
| Change on the day | -2.23% | |
| 52-week range | $328.57–$603.88 | |
| Market capitalisation | $146B | — |
| Price / earnings (trailing) | 51.50 | |
| Shares traded on the day | 2.20M | |
| Beta (volatility vs the S&P 500) | 1.44 |
Why Intuitive Surgical scores 94
Share price, last 12 months -20.1%
$576.20 $460.56
What the price assumes
17.9% a year of free-cash-flow growth for ten years is what a $159.65B market value ( snapshot) asks for.
The price already assumes faster growth than the last 5 years delivered. Anything short of an acceleration leaves room to disappoint. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $3.60B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 12 of the last 12 reports (2024–2026); the stock still fell the next session after 6 of those beats. Average first-session move: 5.2% either way.
- -1.5%Jan ’24
- -2.1%Apr ’24
- +6.8%Jul ’24
- +9.3%Oct ’24
- -4.3%Jan ’25
- +4.2%Apr ’25
- -2.7%Jul ’25
- +15.0%Oct ’25
- +0.1%Jan ’26
- +3.9%Apr ’26
- -11.2%Jul ’26
- -1.2%Oct ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | Beat | -1.2% | +2.9% | |
| Beat | Beat | -11.2% | -14.6% | |
| Beat | Beat | +3.9% | +0.2% | |
| Beat | Beat | +0.1% | -3.1% | |
| Beat | Beat | +15.0% | +19.0% | |
| Beat | Beat | -2.7% | -3.7% | |
| Beat | Beat | +4.2% | +9.9% | |
| Beat | Beat | -4.3% | -5.0% | |
| Beat | Beat | +9.3% | +7.4% | |
| Beat | Beat | +6.8% | +2.5% | |
| Beat | Beat | -2.1% | -0.3% | |
| Beat | Beat | -1.5% | +0.4% |
Beating the estimate has not been enough: the stock fell after 6 of the last 12 beats. The bar it has to clear is the whisper number, not the published one.
What management is saying differently
Management's own words on the Q3 FY2026 call () against Q2 FY2026 (). Analysts' questions are left out.
- New this call: “pricing actions”, “high-volume benign”, “addressable opportunity”, “benign general” — none of them came up in Q2 FY2026.
- Getting louder: “benign procedures” (4 → 12 mentions), “force feedback” (2 → 6 mentions), “general surgery” (1 → 6 mentions).
- Gone quiet: “early stage”, “gen ecosystem”, “cost constrained”, “distributor markets” — regular themes last call, absent this time.
The tone held steady from one call to the next; what changed is the subject matter, not the confidence.
Our track record on this stock
Since the score went from 94 to 94 while the share price moved +12.7% through .
The score has stayed in the Exceptional band across the stretch we have recorded; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 70% of 57 rate it a buy; the average target sits +15.3% from the price of $420.95.
- Last 90 days: 1 upgrade and 0 downgrades among 13 rating actions.
- Our signals: Exceptional band; strongest pillar Financial Safety (95), weakest Valuation (37).
Here we and the crowd agree. Where we differ is on price: our Valuation reading is more cautious than the analysts' targets.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Intuitive Surgical (ISRG): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Munger lens (margin of safety). Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as overvalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Intuitive Surgical (ISRG), and what does it report?
Short answer · as of
Intuitive Surgical is classified among medical instrument and supply makers, yet most of its revenue does not come from selling robots.
Research dated 2026-11-06.
Instruments and accessories, consumed procedure by procedure, form the largest reported line by a wide margin, and services add a further recurring stream from maintenance, repairs, training and installation support. System sales, the part that resembles a capital-equipment business, account for a minority of revenue.
That mix means the reported figures mostly measure how intensively hospitals use the platforms they already own. A period with fewer system placements can still grow if procedure volumes rise, while a slowdown in surgeon adoption would surface first in instruments and accessories rather than in system revenue. Ion carries the same platform logic from surgery into minimally invasive lung biopsy, widening the procedures the installed base can serve.
What do the latest results show for Intuitive Surgical (ISRG)?
Research dated 2026-11-06.
Revenue kept climbing in the latest quarter, and gross profit grew faster than revenue, so the core economics of selling systems, instruments and services improved. The damage sat lower in the income statement: selling, general and administrative expense jumped far above its usual run rate, and that line alone pulled operating profit, net income and diluted earnings per share well below the prior quarter.
The adjusted earnings figure that analysts track still beat the consensus estimate, as it has in every quarter of the displayed history, and revenue also came in ahead of expectations. Operating cash flow reached its highest level in the displayed history, so the expense that hit reported profit did not drain the cash the business generated during the quarter. Management also said on the results call that it continues to expect the same growth range for adjusted operating expenses this year, which places the jump in reported figures rather than in the cost plan management steers by; the company's latest quarterly report is where the expense line is broken down.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $3.05B Oct 20, 2026
- Latest report · revenue estimate
- $2.91B Oct 20, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 20, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 20, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 20, 2026 | $3.05B | $2.91B | $3.0000 | $2.6500 |
| Jul 16, 2026 | $2.89B | $2.83B | $2.8000 | $2.5100 |
| Apr 21, 2026 | $2.77B | $2.62B | $2.8000 | $2.5100 |
| Jan 22, 2026 | $2.87B | $2.76B | $2.5300 | $2.2700 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $2.51B | $704M | $1.95 (diluted) |
| Q4 FY2025 | $2.87B | $795M | $2.21 (diluted) |
| Q1 FY2026 | $2.77B | $822M | $2.28 (diluted) |
| Q2 FY2026 | $2.89B | $818M | $2.29 (diluted) |
What are the financial strengths and risks for Intuitive Surgical (ISRG)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-11-06.
The balance sheet carries no reported debt, cash and investments exceed total liabilities by a wide margin, and operating cash flow has covered capital spending comfortably in every displayed quarter. The distress screen sits far from any warning zone and the quality screen scores well.
The latest quarter still brought movements worth reconciling. Cash and investments fell even as operating cash flow rose, which means money left the balance sheet through uses outside day-to-day operations, and total liabilities increased. Neither threatens solvency, but both deserve a look in the quarterly report before treating the cash pile as fully available.
The operating risk is concentrated in utilization: because instruments and accessories form the largest revenue line, fewer procedures on installed systems would hit revenue faster than slower system placements. The valuation is its own risk, with thin earnings and free-cash-flow yields and a high price-to-earnings multiple, so the share price depends on the installed base continuing to compound.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Rich valuation — a P/E of 51.50 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
What should you watch next at Intuitive Surgical (ISRG)?
Short answer · as of
The next earnings report is expected on Jan 28, 2027.
Research dated 2026-11-06.
The next results release is the natural checkpoint for whether administrative expense returns to its earlier run rate and whether reported operating margin recovers toward the levels of the preceding quarters. Management has said it will update its estimate of the long-term opportunity in soft-tissue surgery around that release and plans to accelerate expansion into countries it does not serve today, so commentary on demand outside the United States matters as much as the headline figures.
Further out, management expects a new facility to begin operations, tying today's capital spending to future capacity. Consensus forecasts have revenue and earnings per share rising in every forecast year, and after the latest results every analyst action on record kept its prior rating; a narrowing of that forecast path would signal that growth assumptions are shifting. A filing early in the current quarter also reported a change among directors or principal officers, and its details belong on the watch list.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Intuitive Surgical compare with its peers?
Short answer
Intuitive Surgical's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-11-06.
Compared with device makers that rely mostly on upfront equipment sales, Intuitive Surgical earns the bulk of its revenue after the sale, from the instruments and services each installed system consumes. A high gross margin, research spending that has risen every year in the displayed history and a balance sheet with no reported debt describe a company that funds its own platform expansion internally rather than through borrowing.
The trade-off is concentration: the same clinical ecosystem drives systems, instruments and services, so anything that slows procedure adoption would touch several revenue lines at once rather than a single product. Ownership is concentrated too, with institutions holding most of the shares and their combined stake rising last quarter even as the number of institutional holders fell. Recent insider activity consists of sales and option-related transactions without open-market purchases, a common pattern where executives are paid largely in stock rather than a signal by itself.
| Company | Price | Market value | Score |
|---|---|---|---|
| $242.61 Nov 18, 2026 | $34.1B | 95 5-pillar Nov 18, 2026 | |
| Intuitive Surgical (ISRG) — this page | $420.95 | $146B | 94 |
| $404.02 Nov 18, 2026 | $28.1B | 92 5-pillar Nov 18, 2026 | |
| $122.86 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $85.93 Nov 18, 2026 | $5.15B | 81 5-pillar Nov 18, 2026 | |
| $75.23 Nov 18, 2026 | $36.1B | 80 5-pillar Nov 18, 2026 | |
| $141.67 Nov 18, 2026 | $8.98B | 77 5-pillar Nov 18, 2026 | |
| $178.48 Nov 18, 2026 | $4.46B | 73 5-pillar Nov 18, 2026 | |
| $39.16 Nov 18, 2026 | $51.5B | 72 5-pillar Nov 18, 2026 | |
| $172.67 Nov 18, 2026 | $11.0B | 71 5-pillar Nov 18, 2026 | |
| $15.37 Nov 18, 2026 | $10.4B | 71 5-pillar Nov 18, 2026 | |
| $216.04 Nov 18, 2026 | $58.9B | 68 5-pillar Nov 18, 2026 | |
| $165.85 Nov 18, 2026 | $6.58B | 61 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $357.44 – $558.00
- Consensus target
- $484.87
- Median target
- $500.00
Consensus record · Captured .
Measured against a quoted price of $420.95 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 10, 2026
- Transactions
- 60
- Identified insiders
- 5
- Purchases
- 0
- Sales
- 11
- Other transactions
- 49
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ISRG in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Coatue | Philippe Laffont | Q3 2026 | 0.47% | $255.20M | Trimmed −20.9% shares |
| ARK Invest | Cathie Wood | Q3 2026 | 0.17% | $30.25M | Added +5.7% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Intuitive Surgical (ISRG)?
Intuitive Surgical Healthcare Stock: Key Questions Answered
Research dated 2026-11-06; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why did Intuitive Surgical's reported profit fall in the latest quarter while revenue rose?
Selling, general and administrative expense jumped far above its recent run rate, pulling operating profit, net income and diluted earnings per share below the prior quarter even as revenue and gross profit grew. The adjusted earnings figure that analysts compare still beat expectations and operating cash flow reached its highest level in the displayed history; the company's quarterly report breaks down the expense line.
How much of Intuitive Surgical's revenue keeps coming after a da Vinci system is installed?
Most of it: instruments and accessories consumed during procedures, plus service contracts for maintenance, repairs and training, make up the large majority of annual revenue, while system sales are a minority. That is why procedure volumes matter more than the number of systems placed in any period.
What is Ion, and how does it fit next to da Vinci?
Ion is Intuitive Surgical's endoluminal platform for minimally invasive diagnostic procedures such as lung biopsies, taking the company from surgery into diagnosis. It follows the same hospital model as da Vinci: a placed system supported by instruments, training and service.
What has Intuitive Surgical said about expanding into new countries?
The update is due around the next scheduled results release, which makes that report the first place to judge the international plan.
What is the ISRG stock price today?
The last price recorded for Intuitive Surgical, Inc. (ISRG), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the ISRG price target?
The analyst consensus price target for Intuitive Surgical, Inc. (ISRG), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research by StockExpertAI Research, 2026-11-06. AI-assisted analysis; source dates are listed under Sources. Reviewed by Sedat ANAK, Founder and Editor-in-Chief, on 2026-11-07.
Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-11-06), by section of the research
ETFs that hold ISRG
Funds in our ETF coverage that list ISRG among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| LGHT ETF | 14.99% | |
| KraneShares Wahed Alternative Income Index ETF (KWIN) | 5.12% | |
| VHT ETF | 2.75% |
